Maria S Govorkova, MD
Ophthalmology · San Jose
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 1
- 1 carrier
- Office
- 1
Offices
1 location · El Camino Health Medical Network LLC · 202 clinicians in this group
Hospitals listed: El Camino Health. That is not proof they admit you there this week.
Plans that list them
1 plan · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Govorkova’s office at (408) 871-3400 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
California Medical Board record
Licence A138095 · Current
Licensed to practise in California · since 2015 · expires 2028-10-31 · Rostov State Medical University.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- El Camino HealthMountain View, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of El Camino Health, which runs 2 hospitalsPatients rate it 4 of 5 · 80% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.291, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.393, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0, Oct 2024 – Sep 2025
See every measure and the patient survey for El Camino Health
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.291 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.393 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.96 (0.12 to 1.79) · 2,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.76 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 167.38 (125.03 to 209.73) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 68 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 185 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 814 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13 · 842 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 361 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 4,633 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.34) · 11,474 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.45) · 11,626 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.14 (1.39 to 4.9) · 2,814 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2 (0.61 to 3.39) · 1,327 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.8 to 3.43) · 2,641 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.39 (4.18 to 14.6) · 1,287 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.57 (3.47 to 9.68) · 1,308 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.14 (0.71 to 3.57) · 827 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.6 (0.05 to 1.15) · 9,460 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.5 · 122 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.993 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.706 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.376 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 218 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.5 · 962 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 3.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -17 · 922 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 18.6 · 860 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.7 · 827 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.1 (4.5 to 8.2) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.4 (10.6 to 16.5) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.7 · 237 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (10 to 16.1) · 1,639 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.8 to 1.1) · 1,619 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,535 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
Original Medicare doctor bills
$103,756
Medicare paid this office $103,756 for 362 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 258 | $39,667 | $117 |
| Removal of cataract with insertion of prosthetic lens | 17 | $13,938 | $536 |
| New patient visit (45+ min) | 100 | $13,817 | $138 |
| Exam of visual field with extended testing | 102 | $7,831 | $59 |
| Imaging of retina | 149 | $6,278 | $36 |
See all 11 services
| Return visit (30+ min) | 258 | $39,667 | $117 |
| Removal of cataract with insertion of prosthetic lens | 17 | $13,938 | $536 |
| New patient visit (45+ min) | 100 | $13,817 | $138 |
| Exam of visual field with extended testing | 102 | $7,831 | $59 |
| Imaging of retina | 149 | $6,278 | $36 |
| Short return visit (20+ min) | 51 | $5,044 | $81 |
| Photography of the retina | 121 | $4,183 | $35 |
| Imaging of optic nerve | 105 | $3,712 | $33 |
| Imaging of front third of eye | 64 | $1,665 | $24 |
| Measurement of corneal curvature and depth of eye | 23 | $1,255 | $36 |
| Ultrasound scan of cornea to determine thickness | 73 | $616 | $8 |
Procedures Medicare counted
| Cataract surgery | 58 | More than 66% of doctors who do this |
Who their Medicare patients are
362 Original Medicare patients in 2024. Average age 76 · Under 65 3% · 85 and older 16% · Women 60% · Also on Medicaid 16% · Health risk score 1.16. Above the middle of the specialty; the typical ophthalmology clinician is at 1.16.
Conditions among them: High blood pressure 75% · Diabetes 47% · Chronic kidney disease 31% · Coronary heart disease 20% · Cancer 15% · Atrial fibrillation 13% · Depression 13% · Heart failure 12% · COPD 10% · Stroke 9% · Dementia 6%.
The office billed $428,482, Medicare allowed $141,334 and paid $103,756; for 1,279 services of 22 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 362 | 1,279 | 76 | 1.16 | $428,482 | $103,756 |
| 2023 | 199 | 722 | 74 | 1.12 | $245,102 | $58,712 |
| 2022 | 155 | 706 | 75 | 1.20 | $240,976 | $57,108 |
| 2021 | 148 | 679 | 75 | 1.35 | $207,716 | $52,871 |
| 2020 | 111 | 480 | 74 | 1.33 | $135,161 | $32,748 |
| 2019 | 206 | 1,174 | 75 | 1.29 | $208,596 | $78,640 |
| 2018 | 139 | 697 | 73 | 1.26 | $117,362 | $49,199 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 11 services
| Return visit (30+ min) | 123 | $20,174 | $114 |
| New patient visit (45+ min) | 72 | $10,520 | $146 |
| Removal of cataract with insertion of prosthetic lens | 13 | $7,476 | $534 |
| Exam of visual field with extended testing | 68 | $5,712 | $54 |
| Short return visit (20+ min) | 50 | $4,359 | $74 |
| Imaging of retina | 68 | $2,829 | $35 |
| Imaging of optic nerve | 70 | $2,605 | $33 |
| Imaging of front third of eye | 36 | $918 | $26 |
| Photography of the retina | 23 | $757 | $33 |
| Measurement of corneal curvature and depth of eye | 14 | $571 | $38 |
| Ultrasound scan of cornea to determine thickness | 38 | $311 | $8 |
2022: 12 services
| Return visit (30+ min) | 92 | $15,279 | $112 |
| Removal of cataract with insertion of prosthetic lens | 12 | $8,556 | $535 |
| New patient visit (45+ min) | 62 | $8,398 | $135 |
| Exam of visual field with extended testing | 65 | $5,652 | $56 |
| Short return visit (20+ min) | 54 | $5,245 | $78 |
| Imaging of optic nerve | 73 | $2,617 | $32 |
| Imaging of retina | 50 | $2,513 | $36 |
| Photography of the retina | 44 | $1,299 | $29 |
| Imaging of front third of eye | 37 | $967 | $24 |
| Measurement of corneal curvature and depth of eye | 13 | $600 | $35 |
| Exam of the internal drainage system of eye | 11 | $311 | $24 |
| Ultrasound scan of cornea to determine thickness | 37 | $288 | $8 |
2021: 11 services
| Return visit (30+ min) | 79 | $13,245 | $117 |
| New patient visit (45+ min) | 78 | $11,954 | $153 |
| Exam of visual field with extended testing | 52 | $4,721 | $60 |
| Short return visit (20+ min) | 45 | $4,540 | $78 |
| Imaging of retina | 47 | $2,215 | $38 |
| Imaging of optic nerve | 50 | $1,911 | $32 |
| Photography of the retina | 48 | $1,723 | $36 |
| Imaging of front third of eye | 49 | $1,382 | $27 |
| Exam of the internal drainage system of eye | 29 | $701 | $21 |
| Measurement of corneal curvature and depth of eye | 12 | $662 | $51 |
| Ultrasound scan of cornea to determine thickness | 51 | $436 | $9 |
2020: 10 services
| Return visit (30+ min) | 51 | $6,149 | $102 |
| New patient visit (45+ min) | 42 | $5,930 | $141 |
| Short return visit (20+ min) | 46 | $4,807 | $66 |
| Exam of visual field with extended testing | 34 | $3,263 | $65 |
| Imaging of retina | 37 | $1,522 | $34 |
| Photography of the retina | 33 | $1,296 | $39 |
| Imaging of front third of eye | 27 | $832 | $28 |
| Imaging of optic nerve | 21 | $822 | $33 |
| Exam of the internal drainage system of eye | 23 | $569 | $22 |
| Ultrasound scan of cornea to determine thickness | 36 | $318 | $9 |
2019: 15 services
| Established patient complete exam of visual system | 118 | $22,427 | $116 |
| Exam of visual field with extended testing | 85 | $6,624 | $62 |
| Established patient problem focused exam of visual system | 57 | $6,461 | $82 |
| Long return visit (40+ min) | 30 | $4,400 | $129 |
| New patient visit (45+ min) | 26 | $3,777 | $145 |
| Examination of eye by ophthalmoscope with retinal drawing | 68 | $3,467 | $25 |
| Imaging of optic nerve | 87 | $3,202 | $32 |
| Exam of the internal drainage system of eye | 87 | $2,738 | $26 |
| Photography of the retina | 46 | $2,423 | $48 |
| Imaging of front third of eye | 67 | $2,303 | $28 |
| Imaging of retina | 54 | $2,291 | $39 |
| Examination of eye by ophthalmoscope with retinal drawing | 32 | $1,866 | $27 |
| Return visit (30+ min) | 17 | $1,655 | $87 |
| Photography of content of eyes | 21 | $486 | $21 |
| Ultrasound scan of cornea to determine thickness | 13 | $148 | $11 |
2018: 12 services
| Established patient complete exam of visual system | 82 | $12,733 | $122 |
| Established patient problem focused exam of visual system | 48 | $6,152 | $87 |
| Exam of visual field with extended testing | 49 | $3,585 | $65 |
| New patient visit (45+ min) | 20 | $2,883 | $144 |
| Photography of the retina | 43 | $2,550 | $58 |
| Examination of eye by ophthalmoscope with retinal drawing | 49 | $2,506 | $24 |
| Long return visit (40+ min) | 14 | $1,910 | $136 |
| Imaging of front third of eye | 47 | $1,663 | $29 |
| Imaging of optic nerve | 40 | $1,488 | $35 |
| Exam of the internal drainage system of eye | 49 | $1,453 | $26 |
| Examination of eye by ophthalmoscope with retinal drawing | 24 | $1,286 | $26 |
| Imaging of retina | 25 | $1,128 | $40 |
Drugs they prescribed that Part D paid
$193,756
Pharmacies billed $193,756 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 1,271) in 2024. At or below the middle of the specialty; the typical ophthalmology clinician is at 0%.
640 generic and 631 brand-name prescriptions · $193,756 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Restasis | 78 | $48,923 | $627 |
| Lumigan | 39 | $23,369 | $599 |
| Miebo | 23 | $17,511 | $761 |
| Rhopressa | 32 | $16,117 | $504 |
| Rocklatan | 27 | $14,484 | $536 |
See all 21 drugs
| Restasis | 78 | $48,923 | $627 |
| Lumigan | 39 | $23,369 | $599 |
| Miebo | 23 | $17,511 | $761 |
| Rhopressa | 32 | $16,117 | $504 |
| Rocklatan | 27 | $14,484 | $536 |
| Ilevro | 28 | $9,877 | $353 |
| Bromfenac | 39 | $7,224 | $185 |
| Simbrinza | 29 | $6,058 | $209 |
| Prednisolone Acetate | 119 | $5,503 | $46 |
| Prolensa | 15 | $5,004 | $334 |
| Inveltys | 15 | $4,270 | $285 |
| Latanoprost | 246 | $3,933 | $16 |
| Cyclosporine | 14 | $3,631 | $259 |
| Brimonidine | 90 | $3,318 | $37 |
| Travoprost | 12 | $1,505 | $125 |
| Moxifloxacin | 80 | $1,398 | $17 |
| Dorzolamide-Timolol | 78 | $1,359 | $17 |
| Timolol Maleate | 72 | $1,171 | $16 |
| Erythromycin | 83 | $1,063 | $13 |
| Dorzolamide | 66 | $479 | $7 |
| Ofloxacin | 12 | $89 | $7 |
Year by year
| 2024 | 1,271 | 353 | 0% (0) | 50% | $193,756 |
| 2023 | 1,046 | 220 | 0% (0) | 52% | $170,398 |
| 2022 | 851 | 188 | 0% (0) | 44% | $105,149 |
| 2021 | 699 | 168 | 0% (0) | 60% | $94,544 |
| 2020 | 364 | 120 | 0% (0) | 54% | $51,785 |
| 2019 | 289 | 98 | 0% (0) | 39% | $25,466 |
| 2018 | 180 | 81 | 0% (0) | 39% | $14,691 |
| 2017 | 106 | 25 | 0% (0) | 19% | $8,049 |
| 2016 | 283 | 67 | None | 24% | $17,942 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 16 drugs
| Restasis | 50 | $36,579 | $732 |
| Prolensa | 68 | $24,726 | $364 |
| Rhopressa | 29 | $18,836 | $650 |
| Lumigan | 20 | $13,701 | $685 |
| Combigan | 14 | $8,582 | $613 |
| Latanoprost | 215 | $6,986 | $32 |
| Simbrinza | 22 | $5,415 | $246 |
| Prednisolone Acetate | 101 | $5,198 | $51 |
| Moxifloxacin | 83 | $5,068 | $61 |
| Brimonidine | 100 | $3,470 | $35 |
| Travoprost | 16 | $2,675 | $167 |
| Dorzolamide | 80 | $2,377 | $30 |
| Dorzolamide-Timolol | 40 | $1,728 | $43 |
| Timolol Maleate | 49 | $639 | $13 |
| Erythromycin | 41 | $487 | $12 |
| Atropine Sulfate | 12 | $436 | $36 |
2022: 14 drugs
| Restasis | 28 | $21,322 | $762 |
| Rhopressa | 27 | $15,309 | $567 |
| Simbrinza | 56 | $14,624 | $261 |
| Lumigan | 22 | $10,720 | $487 |
| Prolensa | 21 | $7,072 | $337 |
| Latanoprost | 238 | $6,701 | $28 |
| Brimonidine | 117 | $4,886 | $42 |
| Travoprost | 11 | $2,795 | $254 |
| Prednisolone Acetate | 53 | $2,583 | $49 |
| Moxifloxacin | 39 | $1,885 | $48 |
| Dorzolamide-Timolol | 41 | $1,348 | $33 |
| Dorzolamide | 53 | $1,123 | $21 |
| Timolol Maleate | 57 | $968 | $17 |
| Erythromycin | 37 | $324 | $9 |
2021: 14 drugs
| Restasis | 37 | $26,214 | $708 |
| Rhopressa | 29 | $12,454 | $429 |
| Lumigan | 18 | $9,740 | $541 |
| Prolensa | 24 | $7,366 | $307 |
| Brimonidine | 64 | $4,266 | $67 |
| Prednisolone Acetate | 66 | $3,861 | $58 |
| Latanoprost | 169 | $3,599 | $21 |
| Rocklatan | 12 | $3,545 | $295 |
| Alphagan P | 12 | $2,770 | $231 |
| Moxifloxacin | 52 | $2,263 | $44 |
| Dorzolamide | 44 | $992 | $23 |
| Erythromycin | 48 | $549 | $11 |
| Dorzolamide-Timolol | 26 | $490 | $19 |
| Timolol Maleate | 12 | $178 | $15 |
2020: 10 drugs
| Restasis | 20 | $14,564 | $728 |
| Lumigan | 15 | $8,954 | $597 |
| Rhopressa | 21 | $7,923 | $377 |
| Brimonidine | 50 | $3,996 | $80 |
| Latanoprost | 95 | $1,504 | $16 |
| Prednisolone Acetate | 26 | $1,345 | $52 |
| Moxifloxacin | 25 | $1,335 | $53 |
| Dorzolamide-Timolol | 23 | $871 | $38 |
| Dorzolamide | 18 | $341 | $19 |
| Erythromycin | 14 | $177 | $13 |
2019: 9 drugs
| Lumigan | 11 | $3,537 | $322 |
| Latanoprost | 88 | $2,377 | $27 |
| Prednisolone Acetate | 29 | $1,312 | $45 |
| Moxifloxacin | 13 | $1,058 | $81 |
| Dorzolamide | 29 | $740 | $26 |
| Dorzolamide-Timolol | 15 | $448 | $30 |
| Brimonidine | 16 | $324 | $20 |
| Timolol Maleate | 16 | $178 | $11 |
| Erythromycin | 11 | $152 | $14 |
2018: 4 drugs
| Prednisolone Acetate | 41 | $2,744 | $67 |
| Latanoprost | 24 | $703 | $29 |
| Polymyxin B Sul-Trimethoprim | 26 | $302 | $12 |
| Erythromycin | 11 | $175 | $16 |
2017: 4 drugs
| Dorzolamide | 16 | $305 | $19 |
| Latanoprost | 15 | $278 | $19 |
| Brimonidine | 21 | $263 | $13 |
| Timolol Maleate | 25 | $244 | $10 |
2016: 8 drugs
| Methazolamide | 22 | $9,691 | $440 |
| Brimonidine | 54 | $1,847 | $34 |
| Prednisolone Acetate | 31 | $1,678 | $54 |
| Latanoprost | 45 | $486 | $11 |
| Dorzolamide | 18 | $420 | $23 |
| Dorzolamide-Timolol | 18 | $396 | $22 |
| Timolol Maleate | 43 | $359 | $8 |
| Ofloxacin | 12 | $183 | $15 |
Money from drug and device companies
$48 in 2023
| 2023 | 2 | 2 | None | $48 |
| 2022 | 1 | 1 | None | $20 |
| 2021 | 4 | 6 | None | $111 |
| 2020 | 2 | 2 | None | $43 |
| 2019 | 4 | 5 | None | $106 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Alcon Vision | Rocklatan | $24 | 1 payment
|
| Thea Pharma | None | $24 | 1 payment
|
See all 2 published payments
| Alcon Vision | Meals · 2023-07-28 | Rocklatan | $24 |
| Thea Pharma | Meals · 2023-05-04 | None | $24 |
See earlier years (2022, 2021, 2020, 2019)
2022: $20
| Kala Pharmaceuticals | Inveltys | $20 | 1 payment
|
2021: $111
| Bausch & Lomb a division of Bausch Health US | Lotemax Sm | $36 | 2 payments
|
| Kala Pharmaceuticals | Inveltys | $33 | 2 payments
|
| Alcon Vision | Argos | $23 | 1 payment
|
| Allergan | Restasis Multidose | $19 | 1 payment
|
2020: $43
| Allergan | Durysta | $23 | 1 payment
|
| Carl Zeiss Meditec AG | None Specified | $19 | 1 payment
|
2019: $106
| Bausch & Lomb a division of Bausch Health US | Vyzulta | $40 | 2 payments
|
| Glaukos | Istent Trabecular Micro-Bypass Stent System | $27 | 1 payment
|
| Aerie Pharmaceuticals | Rhopressa | $22 | 1 payment
|
| Novartis Pharmaceuticals | Xiidra | $17 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 83.6 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1639511488
- Licence
- CA A138095California A138095: Current · expires 2028-10-31
- Gender
- Female
More record details
- Sole proprietor
- Yes
- Taxonomy
- Federal specialty code 207W00000X (207W00000X)
- Mailing address
- 973 University Ave, Los Gatos, CA, 95032
- NPI first listed
- 2013-07-22
- NPI last updated
- 2020-11-30
- NPI record certified
- 2020-11-30
This is when the NPI record was last certified, not a medical board exam.